1. Home
  2. OABI vs IDE Comparison

OABI vs IDE Comparison

Compare OABI & IDE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OABI
  • IDE
  • Stock Information
  • Founded
  • OABI 2012
  • IDE 2010
  • Country
  • OABI United States
  • IDE United States
  • Employees
  • OABI N/A
  • IDE N/A
  • Industry
  • OABI Biotechnology: Pharmaceutical Preparations
  • IDE Finance/Investors Services
  • Sector
  • OABI Health Care
  • IDE Finance
  • Exchange
  • OABI Nasdaq
  • IDE Nasdaq
  • Market Cap
  • OABI 198.2M
  • IDE 173.1M
  • IPO Year
  • OABI N/A
  • IDE N/A
  • Fundamental
  • Price
  • OABI $1.93
  • IDE $11.71
  • Analyst Decision
  • OABI Strong Buy
  • IDE
  • Analyst Count
  • OABI 3
  • IDE 0
  • Target Price
  • OABI $7.00
  • IDE N/A
  • AVG Volume (30 Days)
  • OABI 912.8K
  • IDE 33.5K
  • Earning Date
  • OABI 08-07-2025
  • IDE 01-01-0001
  • Dividend Yield
  • OABI N/A
  • IDE 8.83%
  • EPS Growth
  • OABI N/A
  • IDE N/A
  • EPS
  • OABI N/A
  • IDE N/A
  • Revenue
  • OABI $26,744,000.00
  • IDE N/A
  • Revenue This Year
  • OABI N/A
  • IDE N/A
  • Revenue Next Year
  • OABI $45.65
  • IDE N/A
  • P/E Ratio
  • OABI N/A
  • IDE N/A
  • Revenue Growth
  • OABI 27.07
  • IDE N/A
  • 52 Week Low
  • OABI $1.22
  • IDE $8.61
  • 52 Week High
  • OABI $4.96
  • IDE $10.46
  • Technical
  • Relative Strength Index (RSI)
  • OABI 69.01
  • IDE 71.35
  • Support Level
  • OABI $1.55
  • IDE $11.61
  • Resistance Level
  • OABI $1.73
  • IDE $11.48
  • Average True Range (ATR)
  • OABI 0.10
  • IDE 0.08
  • MACD
  • OABI 0.03
  • IDE 0.00
  • Stochastic Oscillator
  • OABI 100.00
  • IDE 88.64

About OABI OmniAb Inc.

OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.

About IDE Voya Infrastructure Industrials and Materials Fund of Beneficial Interest

Voya Infrastructure, Industrials and Materials Fund is a diversified closed-end management investment company. The primary objective of this investment fund is to achieve total return by combining current income, capital gains, and capital appreciation. To achieve this objective, the fund invests in companies that own and/or operate infrastructure facilities in the infrastructure sector, as well as in a broad range of companies in the industrials and materials sectors that the Sub-Adviser believes will benefit from infrastructure building, renovation, expansion, and utilization.

Share on Social Networks: